Patterns of Care of Cancers and Radiotherapy in Ethiopia

Tara Rick, MPAS, PA-C, MSc1; Biruk Habtamu, MD2; Wondemagegnhu Tigeneh, MD2; Aynalem Abreha, MD2; Yvette van Norden, MSc, PhD1; Surbhi Grover, MD, MPH3; Mathewos Assefa, MD2; and Luca Incrocci, MD, PhD1

PURPOSE Radiotherapy (RT) is an essential component of cancer treatment. There is a lack of RT services in sub-Saharan Africa as well as limited knowledge regarding clinical practices. The purpose of this study was to identify and describe the patterns for RT treatment in Ethiopia.

METHODS AND MATERIALS We performed a retrospective analysis of 1,823 patients treated with cobalt RT at a large referral hospital in Addis Ababa, Ethiopia, from May 2015 through January 2018. Paper charts were reviewed for patient and treatment characteristics. Descriptive statistics were computed using SPSS (IBM, Armonk, NY).

RESULTS Among patients treated for cancer, 98% (n = 1,784) were adults, 78% (n = 1,426) were female, 5% (n = 85) were HIV positive, 30% (n = 555) were from Addis Ababa, and the median age was 48 years (interquartile range [IQR], 38-58 years). Cervical cancer was the most frequent cancer treated (47%, n = 851), followed by breast cancer (15%, n = 274) and head and neck cancer (10%, n = 184). Seventy-three percent of patients (n = 1,339) presented at a late stage, and 62% (n = 1,138) received palliative RT. The wait times were the shortest for patients receiving palliative treatment (median, 0 days; IQR, 0-15 days; n = 1,138), whereas wait times were longer for patients receiving curative treatment (median, 150 days; IQR, 60-210 days; n = 685). Three percent of patients (n = 56) had documented grade 3 or 4 acute toxicity; of these, 59% (n = 33) were patients with head and neck cancer.

CONCLUSION Cervical cancer accounted for half of patients treated; thus, a majority of patients were adult females. Most patients had advanced-stage cancer, and goals of care were palliative. Wait times were long for patients with curative-intent cancer as a result of low capacity for RT services.

J Global Oncol. © 2019 by American Society of Clinical Oncology
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License

INTRODUCTION Radiotherapy (RT) plays an important role in oncology and can be used as the principle treatment method or combined with other modalities to provide cure in up to 40% of patients with a variety of cancers.1 RT is also a highly effective treatment for palliation of cancer symptoms.2 In low- and middle-income countries (LMICs), it is estimated that up to 70% of patients would benefit from RT at some point in their illness as a result of its utility in alleviating symptoms of late-stage disease.3 Moreover, RT is also a cost-effective modality in LMICs where personnel costs are low.4 Despite the clear necessity of RT in LMICs, there is stark inequality in access to care. Nearly 60% of new cancer diagnoses occur in LMICs, whereas <40% of RT equipment is found in these regions.5,6 In sub-Saharan Africa (excluding southern Africa), the disparity is striking, with fewer than one RT machine per 1 million population, 10 times lower than that of North America.5 In fact, more than half the countries in Africa lack a single RT center.7 Therefore, it is estimated that 700 additional RT machines are needed to increase capacity to an acceptable level in Africa.8 This need will only continue to grow because cancer incidence is projected to double in lower resourced regions of Africa by 2040.9 Ethiopia is a low-income country in East Africa with one of the highest populations in sub-Saharan Africa. With the global health burden shifting from communicable to noncommunicable diseases, cancer is now a leading cause of death in Ethiopian adults.5,10 At present, Ethiopia has one functioning cobalt teletherapy machine, serving more than 100 million inhabitants. Tikur Anbessa Specialized Hospital (TASH) in Addis Ababa, the only oncologic referral center in Ethiopia, opened in 1998 and treats more than 1,700 RT patients a year.11 In the 2016 to 2020 Ethiopian National Cancer Control Plan, inadequate RT equipment relative to population need was recognized.12 In response, the government has
Key Objective

There is a paucity of high-quality epidemiological data on radiotherapy utilization patterns in sub-Saharan Africa. This study seeks to describe current patterns of cobalt radiotherapy in Ethiopia and understand unmet needs.

Knowledge Generated

Nearly 2,000 patients were included from the only radiotherapy treating facility in Ethiopia. Cervical cancer accounted for half of patients treated. Most radiotherapy was palliative and wait times for curative patients were long due to low capacity for radiotherapy services.

Relevance

This study provides important epidemiology-based cancer research highlighting the need for increased radiotherapy capacity and providing pivotal information on areas of priority for cancer control planning strategies.

CONTEXT

METHODS AND MATERIALS

Study Design and Participants

This retrospective, cross-sectional study included adult and pediatric patients treated with cobalt RT for malignant diagnoses between May 2015 and January 2018 at TASH in Addis Ababa, Ethiopia. It is estimated that 4,250 patients were treated during the study period, and a random sample of 1,826 charts (43%) were evaluated. Inclusion of all patients treated during the study period was not considered feasible due to difficulty locating paper charts from incomplete registration data in an overcrowded file room. Therefore, charts were randomly identified by hospital administrative staff in the RT department.

General demographic information (age, sex, and region), tumor characteristics (histology and stage), and data regarding specific cancer therapy were extracted from the patients’ paper files. Charts of individuals treated with RT for a benign condition were excluded.

Institutional Characteristics

TASH had one functional cobalt teletherapy unit (Theratron Equinox, Best Theratronics, Ottawa, Ontario, Canada). Brachytherapy capacity was added in 2016. There were 6 radiation oncologists and 28 residents by the end of the study. There were 4 medical physicists, 5 radiation therapists, and 26 oncology nurses on staff.

Diagnosis, Staging of Cancer, and HIV Status

Histology and diagnoses of cancer (International Classification of Diseases–Oncology) were taken from the charts and grouped into categories modeled after the International Agency for Research on Cancer. Advanced imaging (computed tomography [CT] and magnetic resonance imaging [MRI]) was available at TASH; however, the bulk of staging was performed by x-ray and ultrasound. For example, staging for advanced breast and cervical cancers is performed using chest x-ray and abdominal ultrasound. CT staging was reserved for head and neck, thoracic, and select GI cancers and sarcomas. MRI was used in CNS disease, rectal cancer, and select sarcomas.

Staging was classified by International Federation of Gynecology and Obstetrics (FIGO) classification for gynecologic malignancies, Ann Arbor staging for lymphomas, and American Joint Committee on Cancer (AJCC) seventh edition staging for all other cancers except for CNS malignancies and sarcomas, which were not staged but rather classified as operable or inoperable. Multiple myeloma was not staged because of a lack of molecular profiling. The stage at time of pathologic diagnosis was not collected; therefore, stage was determined at the planning visit just before initiating RT.

Cancer Treatment

Patients with cancer were referred from all regions of Ethiopia and nearby countries (ie, Eritrea and Djibouti) for RT. Typically patients were referred in a stepwise approach,
starting at the primary level of care (health center, health post, or primary hospital); then patients were referred to the secondary level (general hospital) before being referred to TASH. At the initial appointment, if RT was indicated, the patients were either given an appointment to return for treatment planning or put on a call list because of high patient volume. Patients with acute symptoms or impending complications from their disease were given priority, followed by patients younger than 25 years old. Treatment aim was assigned at the second visit when treatment was planned and classified as curative (radical, adjuvant, or neoadjuvant) or palliative.

Most treatment planning was performed by anatomic landmarks, even after June 2018 when a planning CT was obtained and reserved for selected complicated planning (ie, approximately 1 of 6 patients with head and neck cancer) predominately for training purposes. Waiting time was calculated as the time between the date of the initial visit and the start of RT (in days). Body site(s) treated, total dose (grays), number of fractions, and dates of external-beam treatment were documented, along with use of brachytherapy when indicated. Any documented acute toxicities (type and grade) were recorded (assessed at end of treatment and the recommended 4-week follow-up, although follow-up after that is often sporadic and toxicity not routinely documented). It was reported whether treatment was completed as planned, interrupted temporarily but completed, or discontinued. Whether patients received chemotherapy and, if so, the timing (before, during, or after RT) were reported. Concurrent chemotherapy was not commonly used given long RT wait times.

Statistical Analysis
Descriptive statistical analysis was performed using IBM SPSS Statistics version 24 (IBM, Armonk, NY).

Ethical and Quality Considerations
Ethical approval was obtained from the Addis Ababa University Clinical Oncology Department Ethical Review Board. The data were deidentified and managed in a secured Microsoft Excel 2018 v16.18 spreadsheet (Microsoft, Redmond, WA). The study was conducted without individual informed consent because the study relied on retrospective data collected as part of routine patient care.

RESULTS
Cancer Distribution and HIV Status
Of 1,826 patient charts evaluated, 3 were excluded (unclassified diagnoses), resulting in 1,823 patients evaluable and included in this analysis. Patient and general treatment characteristics are listed in Table 1. Stage at the initiation of treatment was as follows: 13% not staged (n = 239), 1% stage I (n = 16), 15% stage II (n = 266), 22% stage III (n = 407), and 50% stage IV (n = 895). Thus, three quarters of patients with cancer (n = 1,339) presented at late stage (stage III-IV and inoperable). Five percent of the total cohort (n = 85) reported HIV positivity, and the majority were patients with gynecologic cancer (n = 60, 71% of all HIV-positive patients). Of these gynecologic patients with HIV, 70% (n = 42) had stage III or IV disease. Nearly all HIV-positive patients (n = 83, 98%) reported being treated with HAART.

Treatment Characteristics
Primary indications for palliative RT included pain (n = 368, 32%), pain and bleeding (n = 261, 23%), bleeding (n = 149, 13%), obstructive symptoms (n = 37, 3%), discharge

| TABLE 1. | Patient and General Treatment Characteristics (N = 1,823) |
|----------|---------------------------------------------------------|
| Characteristic | No. of Patients (%) |
| Patient age category, years | | |
| Pediatric (0-17) | 39 (2.1) |
| Adult (≥ 18) | 1,784 (97.9) |
| Median age, years (IQR) | 48 (38-58) |
| Sex | | |
| Female | 1,426 (78.2) |
| Male | 397 (21.8) |
| Region | | |
| Addis Ababa | 555 (30.4) |
| Oromia | 553 (30.4) |
| Amhara | 352 (19.3) |
| SNNPR | 170 (9.3) |
| Tigray | 83 (4.6) |
| Other | 80 (4.3) |
| Not reported | 30 (1.6) |
| HIV status | | |
| Unknown | 1,667 (91.4) |
| Positive | 85 (4.6) |
| Negative | 71 (3.9) |
| Cancer diagnosis | | |
| Cervical | 851 (46.7) |
| Breast | 274 (15.1) |
| Head and neck | 184 (10.1) |
| Sarcoma | 64 (3.5) |
| Colorectal | 57 (3.1) |
| Thyroid | 57 (3.1) |
| Other | 336 (22.6) |
| Stage | | |
| Early (I-II) | 334 (18.3) |
| Late (III-IV) | 1,339 (73.5) |
| Treatment intent | | |
| Palliative | 1,138 (62.4) |
| Curative | 685 (37.6) |

Abbreviations: IQR, interquartile range; SNNPR, Southern Nations, Nationalities, and Peoples’ Region.

*Addis Ababa is a capital/charter city within the Oromia region.
| Cancer Type             | No. of Patients | Patients Who Received Curative-Intent Radiotherapy | Patients Who Received Chemotherapy | Median Wait Time (days; Q1-Q3) | Patients Who Completed Therapy Without Interruption | Patients With Grade 3 or 4 Toxicity* |
|------------------------|-----------------|---------------------------------------------------|-----------------------------------|-------------------------------|-----------------------------------------------------|-----------------------------------|
| Brain, CNS             | 55 (3.0)        | 46 (83.6)                                          | 3 (5.5)                           | 14 (0-60)                     | 55 (100)                                            | 0                                 |
| Early* stage           | 28 (50.9)       | 25 (89.2)                                          | 3 (10.7)                          | 30 (0-112)                    | 28 (100)                                            | 0                                 |
| Late* stage            | 16 (29.1)       | 12 (75.0)                                          | 0                                 | 3.5 (0-30)                    | 16 (100)                                            | 0                                 |
| Locoregional recurrence| 4 (7.2)         | 3 (75.0)                                           | 0                                 | 45 (0-90)                     | 4 (100)                                             | 0                                 |
| Not reported           | 7 (12.7)        | 6 (13.0)                                           | 0                                 | 7 (0-30)                      | 7 (100)                                             | 0                                 |
| Breast                 | 274 (15.0)      | 159 (58.0)                                         | 161 (58.8)                        | 150 (0-240)                   | 272 (99.3)                                          | 0                                 |
| Early stage            | 44 (16.1)       | 44 (100)                                           | 23 (52.2)                         | 180 (150-270)                 | 43 (97.7)                                           | 0                                 |
| Late stage             | 189 (68.9)      | 78 (41.2)                                          | 116 (61.3)                        | 0 (0-210)                     | 189 (100)                                           | 0                                 |
| Locoregional recurrence| 41 (14.9)       | 37 (90.2)                                          | 22 (53.6)                         | 300 (180-500)                 | 40 (97.6)                                           | 0                                 |
| GI                     | 99 (5.0)        | 41 (41.4)                                          | 45 (45.5)                         | 30 (0-150)                    | 91 (91.9)                                           | 6 (6.0)                           |
| Early stage            | 14 (14.1)       | 14 (100)                                           | 10 (71.4)                         | 120 (0-150)                   | 12 (85.7)                                           | 2 (14.2)                          |
| Late stage             | 83 (83.8)       | 25 (30.1)                                          | 35 (42.1)                         | 30 (0-150)                    | 78 (94.0)                                           | 3 (3.6)                           |
| Locoregional recurrence| 2 (2.0)         | 2 (100)                                            | 0                                 | 105                           | 1 (50.0)                                            | 1 (50.0)                          |
| Genitourinary          | 66 (4.0)        | 9 (13.6)                                           | 7 (10.6)                          | 0 (0-0)                       | 64 (97.0)                                           | 2 (3.0)                           |
| Early stage            | 2 (3.0)         | 2 (100)                                            | 1 (50)                            | 120                           | 2 (100)                                             | 0                                 |
| Late stage             | 61 (92.4)       | 6 (9.8)                                            | 5 (8.1)                           | 0 (0-0)                       | 59 (96.7)                                           | 2 (3.3)                           |
| Locoregional recurrence| 3 (4.5)         | 1 (33.3)                                           | 1 (33.3)                          | 0                             | 3 (100)                                             | 0                                 |
| Gynecologic            | 892 (49.0)      | 257 (28.8)                                         | 127 (14.2)                        | 7 (0-90)                      | 837 (93.8)                                          | 14 (1.6)                          |
| Early stage            | 201 (22.5)      | 176 (87.6)                                         | 64 (31.8)                         | 90 (30-150)                   | 193 (96.0)                                          | 6 (3.0)                           |
| Late stage             | 653 (73.2)      | 61 (9.3)                                           | 52 (7.9)                          | 0 (0-30)                      | 608 (93.1)                                          | 7 (1.1)                           |
| Locoregional recurrence| 37 (4.1)        | 19 (51.4)                                          | 11 (29.7)                         | 90 (0-165)                    | 35 (94.6)                                           | 1 (2.7)                           |
| Not reported           | 1 (0.1)         | 1 (0.4)                                            | 0                                 | 1 (100)                      | 0                                                  | 0                                 |
| Head and neck          | 184 (10.0)      | 120 (65.2)                                         | 78 (42.4)                         | 150 (0-210)                   | 143 (77.7)                                          | 33 (17.9)                         |
| Early stage            | 13 (7.1)        | 13 (100)                                           | 2 (15.3)                          | 150 (90-180)                  | 11 (84.6)                                           | 1 (7.7)                           |
| Late stage             | 154 (83.7)      | 94 (61.0)                                          | 71 (46.1)                         | 150 (30-210)                  | 116 (75.3)                                          | 31 (20.1)                         |
| Locoregional recurrence| 10 (5.4)        | 6 (60.0)                                           | 4 (40.0)                          | 165 (127-569)                 | 9 (90.0)                                            | 1 (10.0)                          |
| Not reported           | 7 (3.8)         | 7 (5.8)                                            | 1 (1.3)                           | 120 (30-180)                  | 7 (100)                                             | 0                                 |
| Hematologic            | 32 (2.0)        | 17 (53.1)                                          | 17 (53.1)                         | 0 (0-0)                       | 31 (97.0)                                           | 0                                 |
| Early stage            | 11 (33.3)       | 11 (100)                                           | 5 (45.4)                          | 0 (0-0)                       | 11 (100)                                            | 0                                 |
| Late stage             | 9 (28.1)        | 0                                                  | 8 (88.8)                          | 0 (0-0)                       | 8 (88.9)                                            | 0                                 |
| Locoregional recurrence| 4 (12.5)        | 3 (75.0)                                           | 2 (50.0)                          | 0 (0-2)                       | 4 (100)                                             | 0                                 |
| Not reported           | 8 (25)          | 3 (17.6)                                           | 2 (11.8)                          | 0 (0-0)                       | 8 (100)                                             | 0                                 |
| Sarcoma                | 64 (4.0)        | 27 (42.2)                                          | 31 (48.4)                         | 1 (0-150)                     | 62 (97.0)                                           | 1 (1.6)                           |
| Early stage            | 17 (26.6)       | 16 (94.1)                                          | 7 (41.2)                          | 150 (60-210)                  | 17 (100)                                            | 0                                 |
| Late stage             | 33 (51.6)       | 4 (12.1)                                           | 19 (57.6)                         | 0 (0-75)                      | 33 (100)                                            | 0                                 |
| Locoregional recurrence| 10 (15.6)       | 5 (50.0)                                           | 4 (40.0)                          | 45 (0-129)                    | 9 (90.0)                                            | 1 (10.0)                          |
| Not reported           | 4 (6.3)         | 2 (7.4)                                            | 1 (3.2)                           | 1 (0-248)                     | 3 (75.0)                                            | 0                                 |

(Continued on following page)
TABLE 2. Treatment Characteristics by Tumor Category (Continued)

| Cancer Type | No. of Patients | Patients Who Received Curative-Intent Radiotherapy | Patients Who Received Chemotherapy | Median Wait Time (days; Q1-Q3) | Patients Who Completed Therapy Without Interruption | Patients With Grade 3 or 4 Toxicity* |
|-------------|----------------|---------------------------------|-----------------------------------|-----------------------------|-----------------------------------------------|----------------------------------|
| Skin        | 33 (2.0)       | 6 (18.2)                        | 10 (30.3)                         | 7 (0-195)                   | 33 (100)                                      | 0                                |
| Early stage | 1 (3.0)        | 1 (100)                         | 0                                 | 150                        | 1 (100)                                       | 0                                |
| Late stage  | 24 (72.7)      | 1 (4.2)                         | 6 (25.0)                          | 0 (0-30)                    | 24 (100)                                      | 0                                |
| Locoregional recurrence | 8 (24.2) | 4 (50.0)                        | 4 (50.0)                          | 270 (165-349)              | 8 (100)                                       | 0                                |
| Thoracic    | 36 (2.0)       | 0 (0)                           | 9 (25.0)                          | 0 (0-0)                    | 36 (100)                                      | 0                                |
| Early stage | 0              | 0                               | 0                                 | 0                          | 0                                             | 0                                |
| Late stage  | 35 (97.2)      | 0                               | 8 (22.9)                          | 0 (0-0)                    | 35 (100)                                      | 0                                |
| Locoregional recurrence | 1 (2.8) | 0                              | 1 (100)                           | 0                          | 1 (100)                                       | 0                                |
| Thyroid     | 57 (3.0)       | 2 (3.5)                         | 2 (3.5)                           | 0 (0-0)                    | 56 (98.2)                                     | 0                                |
| Early stage | 2 (3.5)        | 1 (50.0)                        | 0                                 | 90                         | 2 (100)                                       | 0                                |
| Late stage  | 52 (91.2)      | 0                               | 2 (100)                           | 0 (0-0)                    | 50 (98.0)                                     | 0                                |
| Locoregional recurrence | 3 (5.2) | 1 (50.0)                        | 0                                 | 656                        | 3 (100)                                       | 0                                |
| Unknown primary | 31 (2.0) | 1 (3.2)                         | 5 (16.1)                          | 0 (0-0)                    | 30 (96.8)                                     | 0                                |
| Early stage | 1 (3.2)        | 1 (100)                         | 0                                 | 120                        | 0                                             | 0                                |
| Late stage  | 30 (96.8)      | 0                               | 5 (16.7)                          | 0 (0-0)                    | 30 (100)                                      | 0                                |
| Locoregional recurrence | 0 | 0                             | 0                                 | 0                          | 0                                             | 0                                |

NOTE. Data presented as No. (%) unless otherwise indicated. Abbreviation: Q, quarter.

*Based on Common Terminology Criteria for Adverse Events version 5.0.

Early stage indicates American Joint Committee on Cancer (AJCC)/International Federation of Gynecology and Obstetrics (FIGO) stage I or II or operative sarcoma or CNS tumor.

Late stage indicates AJCC/FIGO stage III or IV or nonoperative sarcoma or CNS tumor.

(n = 32, 2.8%), neurologic symptoms (n = 25, 2.2%), other (n = 3), and not reported (n = 263, 23%). The cancer categories with highest percentage of curative intent included brain and CNS (84%), head and neck (65%), breast (58%), and hematologic malignancies (53%; Table 2). The tumors least often treated with curative intent were thoracic (lung and thymic, 0%), unknown primary (3%), thyroid (4%), genitourinary (14%), and skin (18%). As expected, patients who presented at an early stage were more likely to be treated with curative intent. Twenty-seven percent of patients (n = 494) received chemotherapy at some point in their treatment; of these, the predominate cancer types were breast cancer (59%), hematologic malignancies (53%), sarcoma (48%), GI malignancies (45%), and head and neck cancers (42%).

**Treatment Completion and Toxicity**

Ninety-four percent of patients (n = 1,710) completed therapy without interruption, and 3% (n = 56) had documented grade 3 or 4 acute toxicity. Lowest rates of completion (without interruption) were in patients with head and neck cancer (78%, n = 143), who also had the highest rates of grade 3 or 4 acute toxicity (17.9%, n = 33).

**Dosing Regimens**

The most frequent RT regimen was 20 Gy in 2 fractions for advanced-stage cervical cancer and 20 Gy in 5 fractions for many other advanced-stage cancers (n = 672, 37%), suggestive of palliative treatment (Table 3).

**Wait Times**

The wait times were the shortest for patients who received short palliative treatment (median, 0 days; interquartile range [IQR], 0-15 days; n = 1,138), whereas wait times were long for patients who received curative treatment (median, 150 days; IQR, 60-210 days; n = 685).

**DISCUSSION**

This cross-sectional study on the patterns of RT in Ethiopia is, to our knowledge, the largest descriptive analysis of RT use for all cancers in Ethiopia and, more broadly, the African continent. In our cohort, women disproportionately carried the cancer burden as a result of high rates of breast and cervical cancer, consistent with published data from the Addis Ababa population-based cancer registry that breast and cervical cancer account for nearly a third of all cancers, followed by colorectal cancer,
TABLE 3. Most Common dosing Regimen by Diagnosis

| Diagnosis and Dosing Regimen | No. of Patients (%) |
|------------------------------|---------------------|
| Cervical cancer              | 851                 |
| Early stage                  | 197                 |
| Pelvis, 40-50 Gy in 2-Gy fractions + brachytherapy | 91 (46) |
| Pelvis, 40-50 Gy in 2-Gy fractions + 20-26 Gy in 2-Gy fraction boosta | 55 (30) |
| Late stage                   | 621                 |
| Pelvis, 20 Gy in 10-Gy fractions | 387 (62) |
| Locoregional recurrence      | 32                  |
| Pelvis, 46 Gy in 2-Gy fractions | 9 (28)  |
| Breast cancer                | 274                 |
| Early stage                  | 44                  |
| Chest wall, 39 Gy in 3-Gy fractions ± 5-16 Gy in 2-Gy fraction boost | 38 (86)  |
| Late stage                   | 189                 |
| Bone or brain, 20 Gy in 5-Gy fractionsb | 89 (47) |
| Locoregional recurrence      | 41                  |
| Chest wall, 39 Gy in 3-Gy fractions ± 10-18 Gy in 2-Gy fraction boost | 26 (63)  |
| Head and neck cancer         | 184                 |
| Early stage                  | 13                  |
| Head and neck, 66-70 Gy in 2-Gy fractions | 7 (54)  |
| Late stage                   | 154                 |
| Head and neck, 60-70 Gy in 2-Gy fractions | 90 (58) |
| Locoregional recurrence      | 10                  |
| Head and neck, 60-66 Gy in 2-Gy fractions | 6 (60)  |

aStandard regimen before brachytherapy capacity.  
bDosing for metastatic disease.

non-Hodgkin lymphoma, leukemia, prostate cancer, and thyroid cancer. According to the International Agency for Research on Cancer, cervical cancer is the fourth most common cancer in women worldwide, but it is the most frequent cancer in women in many countries in sub-Saharan Africa where incidence is the highest in the world. This is a stark disparity because 85% of women diagnosed with cervical cancer (a largely avoidable disease) live in LMICs with limited access to preventative services and treatment.

The prevalence of HIV in our cohort was 3-fold higher than that of the general Ethiopian population (4.6% vs 1.5%, respectively), which has also been observed in Uganda. A majority of patients in the study were female. Females have a higher prevalence of HIV than males; in addition, HIV is an independent risk factor for cervical cancer, which is preferentially treated by RT. A study by Kantelhardt et al reported a 9% prevalence of HIV in Ethiopian patients with cervical cancer, and our study found a similar rate in Ethiopian patients with gynecologic cancers. These HIV rates in patients with cervical cancer are lower compared with other countries in sub-Saharan Africa as a result of the overall lower prevalence of HIV in Ethiopia.

Nearly three-quarters of all patients with cancer in this study presented at late stage, which is consistent with findings from other countries in sub-Saharan Africa. This is at least partially a result of the lack of national screening programs in most African regions. In addition, a great majority of cancer care in Ethiopia is centralized to the tertiary level of care. Even palliative care services are centralized and not initiated until a patient is seen at TASH, a system that is critically over capacity. Our study not only emphasizes the need for high-importance, low-cost prevention and screening strategies in Ethiopia and the African continent at large, with the aim of diagnosing cancer at early stages when RT and other treatment modalities can be used with curative intent, but also emphasizes the need to decentralize palliative care and train primary- and secondary-level providers to provide palliative care at the community level.

In most cases of palliative RT, patients returned to their communities and were not seen in follow-up; therefore, documented toxicity was overall low. Patients with head and neck cancer had the highest rates of treatment interruption and the highest rates of grade 3 or 4 toxicity, which is similar to the literature. To our knowledge, there are no other published reported rates of acute RT toxicity in head and neck cancer in sub-Saharan Africa. Moelle et al reported grade 3 early toxicity in 5% of patients with cervical cancer who received curative RT in the same center in Ethiopia, which was a considerably higher rate than in this study. This is at least partially a result of the addition of brachytherapy during our study period, which alleviates the need for an external-beam boost, causing higher toxicity to the surrounding tissue.

One of the most striking findings of this study was the long waiting times of patients with potential for cure. Waiting times are influenced by the priority given to the large burden of patients who require palliation of debilitating symptoms such as pain, obstruction, or bleeding and risk reduction of emergent conditions such as pathologic fracture and cord compression. In addition, priority is given to younger patients. These reasons, coupled with limited treatment availability, played a major role in the observed wait times. This situation leads to a long wait for many individuals with potentially curative disease, risking their conversion to the palliative category as the disease progresses. Kantelhardt et al showed comparable rates of late-stage cervical cancer and wait times in Ethiopia but also reported that the proportion of patients with late-stage cervical cancer (FIGO stage IIIb and greater) increased from 44% to 69% during the wait time. In our study, stage was recorded immediately before starting RT; therefore, the rates of conversion during the wait time are unknown; however, it is possible that a 20% conversion also occurred.
during the waiting times. A correlation has been made between long wait time and worse outcomes in head and neck cancer; a Taiwanese study showed worse outcomes after 40-day delay, and a larger Dutch study showed worse outcome after 90 days.\textsuperscript{29,30} The median wait time for radical and adjuvant head and neck cancer was 5 months. This finding is of importance because it calls for better planning and stratification of treatment in an attempt to increase cure rates for early-stage tumors. It is likely that as more RT equipment is available in the region, waiting times will decrease and better curative-intent stratification will occur.

In regard to RT dosing at TASH, conventional fractionation is preferred for all curative diagnoses except for breast cancer, for which the hypofractionation schedule is used based on the START-A trial to maximize limited RT resources.\textsuperscript{31} Since brachytherapy was obtained in 2016, all curative patients are receiving brachytherapy unless probe insertion is not possible. Furthermore, because of limited capacity, concurrent chemoradiation is not yet feasible for cervical cancer.

There are multiple limitations to this study. First, the retrospective nature narrows the qualitative descriptors of the data to those previously recorded in the patient file. Second, the data collection was completed after approximately half of the estimated cohort was enrolled as a result of feasibility because data analysis at 1,823 patients was unchanged from data analysis after 500 patients, indicating a random sample. Third, cancer staging was performed by the treating physician through standardized methods agreed upon throughout the department. However, the eighth and latest edition of the AJCC staging system was not used because of lack of molecular diagnostics. For example, estrogen receptor–, progesterone receptor–, and human epidermal growth factor receptor–status is not routinely determined in patients with breast cancer. However, this is a limitation applicable to many resource-limited areas and speaks of the need to create differential guidelines in these settings. Finally, the availability of documented follow-up data were rare; thus, late toxicities and patient outcomes were not available. Information about acute toxicity was also not routinely recorded and likely significantly underreported, highlighting the need for future prospective studies that can more accurately describe toxicity and outcomes. Because more RT equipment needs to be purchased, it is imperative for stakeholders to have accurate outcome information from the African context about different equipment choices to help inform decisions.

To our knowledge, this study is the largest of its kind, describing the basic epidemiology and findings of more than 1,800 patients treated with cobalt RT at a large referral hospital in sub-Saharan Africa. Most patients were treated for gynecologic cancer and presented at advanced stage. The goal of treatment was palliative in a majority of patients, and limited radiation capacity led to long waiting times. The need for increased RT capacity is critical, and future prospective studies are needed on outcomes for RT modalities in sub-Saharan Africa.
